» Articles » PMID: 38581263

Cell Membrane-Camouflaged Chitosan-Polypyrrole Nanogels Co-Deliver Drug and Gene for Targeted Chemotherapy and Bone Metastasis Inhibition of Prostate Cancer

Overview
Date 2024 Apr 6
PMID 38581263
Authors
Affiliations
Soon will be listed here.
Abstract

The development of functional nanoplatforms to improve the chemotherapy outcome and inhibit distal cancer cell metastasis remains an extreme challenge in cancer management. In this work, a human-derived PC-3 cancer cell membrane-camouflaged chitosan-polypyrrole nanogel (CH-PPy NG) platform, which can be loaded with chemotherapeutic drug docetaxel (DTX) and RANK siRNA for targeted chemotherapy and gene silencing-mediated metastasis inhibition of late-stage prostate cancer in a mouse model, is reported. The prepared NGs with a size of 155.8 nm show good biocompatibility, pH-responsive drug release profile, and homologous targeting specificity to cancer cells, allowing for efficient and precise drug/gene co-delivery. Through in-vivo antitumor treatment in a xenografted PC-3 mouse tumor model, it is shown that such a CH-PPy NG-facilitated co-delivery system allows for effective chemotherapy to slow down the tumor growth rate, and effectively inhibits the metastasis of prostate cancer to the bone via downregulation of the RANK/RANKL signaling pathway. The created CH-Ppy NGs may be utilized as a promising platform for enhanced chemotherapy and anti-metastasis treatment of prostate cancer.

Citing Articles

Nanoparticles and bone microenvironment: a comprehensive review for malignant bone tumor diagnosis and treatment.

Guan Y, Zhang W, Mao Y, Li S Mol Cancer. 2024; 23(1):246.

PMID: 39487487 PMC: 11529338. DOI: 10.1186/s12943-024-02161-1.


Identification of cancer stem cell-related genes through single cells and machine learning for predicting prostate cancer prognosis and immunotherapy.

Wang Y, Ma L, He J, Gu H, Zhu H Front Immunol. 2024; 15:1464698.

PMID: 39267762 PMC: 11390519. DOI: 10.3389/fimmu.2024.1464698.


Multi-omics analysis and experimental validation of the value of monocyte-associated features in prostate cancer prognosis and immunotherapy.

Wang Y, Li C, He J, Zhao Q, Zhou Y, Sun H Front Immunol. 2024; 15:1426474.

PMID: 38947325 PMC: 11211272. DOI: 10.3389/fimmu.2024.1426474.